Catalent, Inc. Common Stock (NY:CTLT)

63.48 UNCHANGED

Last Price Updated: 7:00 PM EST, Dec 17, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Catalent, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026

February 27, 2026

As of February 27, 2026, the narrative surrounding Novo Nordisk (NYSE: NVO) has undergone a dramatic transformation. For the better part of three years, the Danish pharmaceutical giant was the...

Via Finterra

Topics Economy Intellectual Property

Novo Nordisk Navigates a GLP-1 Gold Rush: Soaring Obesity Drug Sales Clash with Revised Outlook Amidst Mounting Competition

September 16, 2025

Copenhagen, Denmark – Pharmaceutical giant Novo Nordisk (NYSE: NVO) has reported a robust second quarter for 2025, with impressive revenue and net income figures largely propelled by the formidable...

Via MarketMinute

Topics Earnings Economy Intellectual Property

FDA Flags Alarming Contamination At Novo Nordisk Indiana Plant, Including Cat Hair, Bacteria, And Foreign Particles ↗

August 25, 2025

Novo Nordisk's acquired facility faces scrutiny over recurring contamination, incomplete investigations, and ineffective corrective actions.

Via Benzinga

Catalent Announces New Board Appointments

February 20, 2025

From Catalent, Inc.

Via Business Wire

Lennox To Join S&P 500 Index, Replacing Catalent ↗

December 18, 2024

Lennox, an AI cooling play, will join the S&P 500 before the open on Dec. 23. Bill Holdings will take its pace in the S&P Midcap 400.

Via Investor's Business Daily

Topics Artificial Intelligence Stocks

Novo Holdings Completes Acquisition of Catalent

December 18, 2024

From Catalent, Inc.

Via Business Wire

Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent ↗

December 16, 2024

Novo Nordisk unveils a $1.2 billion production facility in Denmark and finalizes Catalent acquisition, with financial and operational impacts ahead.

Via Benzinga

Catalent and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction

December 14, 2024

From Catalent, Inc.

Via Business Wire

Catalent and Novo Holdings Receive European Commission Unconditional Approval for Pending Transaction

December 06, 2024

From Catalent, Inc.

Via Business Wire

The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion Market ↗

December 05, 2024

An age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in obesity.

Via Investor's Business Daily

Catalent, Inc. Reports First Quarter Fiscal 2025 Results

November 05, 2024

From Catalent, Inc.

Via Business Wire

Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition ↗

October 23, 2024

Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition.

Via Benzinga

Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings

October 21, 2024

From Catalent, Inc.

Via Business Wire

After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent ↗

October 18, 2024

Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over reduced competition in critical areas like diabetes, obesity treatments,...

Via Benzinga

Jim Cramer: 'We Need More Uranium,' Recommends This Stock; Says Novo Nordisk 'Doesn't Hold A Candle' To Big Pharma Rival ↗

October 15, 2024

Jim Cramer believes Uranium Energy Corp. is going higher, thanks to a recent acquisition deal. Novo Nordisk faces antitrust concerns while Halliburton gets a Buy rating from BofA Securities.

Via Benzinga

Catalent Signs Agreement to Sell Somerset, NJ Oral Solids Facility

October 14, 2024

From Catalent, Inc.

Via Business Wire

FTC Faces Pressure to Block Novo Nordisk-Catalent Merger Over Antitrust Fears ↗

October 10, 2024

Concerns are rising as Novo Nordisk's $16.5 billion bid to acquire Catalent faces scrutiny from the FTC. Critics argue the merger could harm competition in the GLP-1 market, potentially driving up...

Via Benzinga

Four Stocks To Watch This Week - Tuesday, Oct. 01 ↗

October 01, 2024

A flat week that was anticipated, one notable event was China's stimulus package announcement, which sent China-related stocks soaring. Most of these stocks surged without prior consolidations/warning...

Via Talk Markets

Tempus AI Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗

September 16, 2024

A Relative Strength Rating upgrade for Tempus AI shows improving technical performance.

Via Investor's Business Daily

Topics Artificial Intelligence

Catalent, Inc. Reports Fourth Quarter and Fiscal 2024 Results

August 29, 2024

From Catalent, Inc.

Via Business Wire

Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater ↗

August 16, 2024

A small telemedicine company just entered the weight loss race.

Via The Motley Fool

Catalent Completes $25 Million Expansion of its Clinical Supply Facility in Schorndorf, Germany

July 16, 2024

From Catalent, Inc.

Via Business Wire

Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty ↗

June 21, 2024

Catalent shares rise after Sarepta Therapeutics' Elevidys expanded approval. Despite uncertainties, Catalent's risk/reward profile improves.

Via Benzinga

S&P 500 Giants Lead Five Healthy Stocks Near Buy Points ↗

June 01, 2024

Eli Lilly is in a buy zone, while rival Novo Nordisk forged a lower entry.

Via Investor's Business Daily

Topics Stocks

Catalent Stockholders Approve Transaction with Novo Holdings

May 29, 2024

From Catalent, Inc.

Via Business Wire

Soaring Eli Lilly Stock Could Climb Another 24% According to a Wall Street Analyst. Is the Stock a Buy Now? ↗

May 28, 2024

Plowing $9 billion into a manufacturing facility could help a successful tirzepatide launch reach new heights.

Via The Motley Fool

Hedge Funds Tweak Portfolios In Q1: Marvell, TD Synnex, AES Get More Love As Focus Shifts To AI ↗

May 24, 2024

Hedge funds are looking for high-return opportunities beyond the mega-cap tech giants preferring to focus on cyclical sectors and AI.

Via Benzinga

CTLT Stock Earnings: Catalent Misses EPS, Misses Revenue for Q3 2024 ↗

May 09, 2024

CTLT stock results show that Catalent missed analyst estimates for earnings per share and missed on revenue for the third quarter of 2024.

Via InvestorPlace

Catalent, Inc. Reports Third Quarter Fiscal 2024 Results

May 08, 2024

From Catalent, Inc.

Via Business Wire

Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition ↗

May 02, 2024

The Danish pharmaceutical company is now shipping more introductory doses of Wegovy to the U.S., as it grapples with supply constraints and competition from Eli Lilly.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.